Eli Lilly has entered a strategic collaboration with Profluent, an artificial intelligence-driven biotechnology company, to develop next-generation gene editing tools. These tools aim to enable the insertion of entire genes into patients, potentially expanding treatment options for genetic disorders.
The partnership, announced on Tuesday, outlines a framework for joint research and development, though specific details—such as the number of programs, targeted diseases, or upfront payment amounts—have not been disclosed.
Under the terms of the agreement, Eli Lilly could pay Profluent up to $2.25 billion in milestone payments if all research efforts succeed. The financial structure reflects the high stakes of advancing gene editing technology, which holds promise for treating a range of genetic conditions.
This collaboration aligns with Eli Lilly’s broader expansion into genetic medicine. The pharmaceutical giant, buoyed by record revenues from its obesity and diabetes treatments, has significantly invested in the sector. Recent initiatives include the establishment of a new genetic medicine center in Boston and the acquisition of multiple gene editing and gene therapy companies over the past several years.
Related articles
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
STAT+ Roundup: New Hires and Promotions in Biotech and Pharma
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
UK Political Shake-Up Could Reshape Global Drug Pricing Policies
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
Why Changing Pill Colors and Shapes at 73 Are More Than Just an Annoyance
At the ripe old age of 73, I take six drugs — four prescription and two over-the-counter pills — every day. I keep careful track of them. But recently...
U.S. Pressures Germany to Increase Payments for Prescription Drugs Amid Trade Tensions
WASHINGTON — Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals. The meeting, between U.S....
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...